Research
Hormonal
Leptin and estrogen signaling modulate the skeleton's sensitivity to mechanical loading, with leptin deficiency requiring higher body weight to achieve equivalent bone mass.
Hormonal health, particularly leptin and estrogen levels, influences how effectively your bones respond to body weight. Hormonal imbalances can decouple the protective effect of weight on bones, meaning weight management alone may not be sufficient for bone health in all individuals.
GoodQualifiesHIGH confidence
Leptin alters the sensitivity of the skeleton to body weight changes... ob/ob mice require a much higher body weight to achieve a bone mass equivalent to WT.
Why this rating
Based on animal studies (mice) with clear hormonal manipulation.
Source
Influence of body weight on bone mass, architecture and turnover
Urszula T. Iwaniec et al. · Journal of Endocrinology · 2016
DOI 10.1530/joe-16-0089
narrative_reviewCited 187×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weightlessness and reduced mechanical loading (e.g., spaceflight, bed rest) cause rapid, site-specific bone loss, particularly in weight-bearing bones, with recovery being significantly slower than the rate of loss.Strong
- Increased body weight and mechanical loading via the mechanostat increase bone mass and reduce osteoporosis prevalence, but this benefit plateaus or reverses at morbid obesity levels due to compromised bone quality and altered fracture mechanics.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →